Gambian trypanosomiasis

(redirected from gambiense sleeping sickness)

Gam·bi·an try·pan·o·so·mi·a·sis

a chronic disease of humans caused by Trypanosoma brucei gambiense in northern and sub-Saharan Africa from Senegal east to Sudan and Uganda; characterized by splenomegaly, drowsiness, an uncontrollable urge to sleep, and the development of psychotic changes; basal ganglia and cerebellar involvement commonly lead to chorea and athetosis; the terminal phase of the disease is characterized by wasting, anorexia, and emaciation that gradually leads to coma and death, usually from intercurrent infection.

Gambian trypanosomiasis

[gam′bē·ən]
a usually chronic form of African trypanosomiasis, caused by the parasite Trypanosoma brucei gambiense. An infected individual may have relatively mild symptoms for months or years before developing the neurological symptoms of the terminal stage. Also called Trypanosoma brucei gambiense, West African sleeping sickness. Compare Rhodesian trypanosomiasis. See also African trypanosomiasis.

Gam·bi·an try·pa·no·so·mi·a·sis

(gam'bē-ăn trī-pan'ō-sō-mī'ă-sis)
A chronic disease of humans caused by Trypanosoma brucei gambiense in Africa; characterized by splenomegaly, drowsiness, an uncontrollable urge to sleep, and the development of psychotic changes; basal ganglia and cerebellar involvement commonly lead to chorea and athetosis; the terminal phase of the disease is characterized by wasting, anorexia, and emaciation that gradually lead to coma and death, usually from intercurrent infection.
Synonym(s): chronic trypanosomiasis.
References in periodicals archive ?
Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea.
gambiense sleeping sickness transmission allow for the estimation of this potential benefit at population level.
Analytical tools for planning cost-effective surveillance in Gambiense sleeping sickness.
The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.
Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.
Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.
Epidemiological studies on the animal reservoir of Gambiense sleeping sickness.